Abstract:343 Objectives: Secondary injury persists after stroke onset, and deteriorates tissue and function outcomes in the long run. Peri-infarct depression (PID) is a validated pathological mechanism during secondary injury. As a depolarization wave spreading across the cortex, PID increases regional glucose demand and worsens supply-demand mismatch after stroke, thus expands infarct size. Peri-infarct depression emerges as a potential therapeutic target during stroke treatment. However, detection of PID with electrocorticography (ECoG) is invasive and has a restriction in further clinical practice. Taken metabolic challenge imposed by PID, we tend to monitor metabolic state of stroke brain by FDG PET imaging, and visualize metabolic stress induced by peri-infarct depression, thus provide a non-invasive method to monitor PID related injury. Method: Photochemical method is applied to induce a 1[asterisk]1mm infarction in rat cortex. After stroke, FDG PET imaging, ECoG recording, laser speckle imaging and rotarod test are performed daily for the first week, then weekly during the 2nd week to 4th week. Regional metabolic alteration is analyzed with SPM software. Immunohistochemical staining, western blot assay, and bioluminescence imaging are employed to assess metabolic state and mitochondria function. In vitro experiments on cortical neurons from embryonic day 18 rats are performed to investigate mechanism underlying metabolic change induced neuron dysfunction. Results: FDG PET imaging indicates growing regions with increased glucose uptake around infarct core during first week after stroke. The change in glucose uptake has no correlation with regional blood supply, while apparently affected by the occurrence of PID. Results of rotarod test demonstrate deteriorated neurological performance along with expanded metabolic change and increased incidents of PID. From the 2nd week after stroke, increased FDG uptake gradually decreases, and ends up with low uptake compared with healthy brain. Histological analysis indicates overall increased glycolysis, and reduced mitochondria function in brain regions with increased FDG uptake, where gliosis and increased microglia accumulation occur in chronic state. Regional metabolic alteration is mostly accompanied with overexpression of HIF1a. In vitro, 1uM DMOG is applied to elevate expression of HIF1a and induce the metabolic change in cultured neurons. With suppressed mitochondria function, neurons firstly exhibit increased intracellular calcium concentration, then neurite spines diminish and neurites degeneration. Administration of resveratrol in stroke rats at chronic phase of stroke or neurons treated with DMOG could efficiently increase mass and function of mitochondria, and improve tissue and functional consequence. Conclusion: FDG PET imaging is reliable to reflect metabolic stress imposed by peri-infarct depression. Peri-infarct depression leads to the metabolic change in neurons, including suppression of mitochondria function and overactivation of glycolysis, thus deteriorate functional and tissue consequence. The insults from PID could be alleviated by improving mitochondria function.

PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke

11 C-NMSP/ 18 F-FDG Micropet to Monitor Neural Stem Cell Transplantation in a Rat Model of Traumatic Brain Injury

Using MicroPET Imaging in Quantitative Verification of the Acupuncture Effect in Ischemia Stroke Treatment

FDG PET Imaging As A Non-invasive Method to Demonstrate Peri-infarct Depression after Stroke

Spatiotemporal Pet Imaging Of Dynamic Metabolic Changes After Therapeutic Approaches Of Induced Pluripotent Stem Cells, Neuronal Stem Cells, And A Chinese Patent Medicine In Stroke

Using MicroPET Imaging in Quantitative Verification of Acupuncture Effect in Ischemia Stroke Treatment

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding

Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease

Imaging synaptic density in ageing and Alzheimer's Disease with [18F]-SynVesT-1

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

PET Demonstrates Functional Recovery after Treatment by Danhong Injection in a Rat Model of Cerebral Ischemic-Reperfusion Injury

Cerebral [18F]AIF-FAPI-42-Based PET Imaging of Fibroblast Activation Protein for Non-invasive Quantification of Fibrosis After Ischemic Stroke

GMP-compliant automated radiosynthesis of [18F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2 A (SV2A)

Pet Demonstrates Functional Recovery after Transplantation of Induced Pluripotent Stem Cells in A Rat Model of Cerebral Ischemic Injury

Voxel-wise regression without intensity normalization provides better sensitivity when identifying injury regions after stroke in FDG-PET images

In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol

Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with 18F-SynVesT-1 positron emission tomography imaging

In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review

Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)

The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An 18F-SynVesT-1 PET/MR study